

ERRATUM

B Gazzard on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)

Table 1 in the above-mentioned paper [1] was represented incorrectly. Please see below for the correct table:

Table 1 Cost of preferred regimens as per Table 4, showing the monthly (30-day) cost as set out in list price (May 2006) + VAT at 17.5% in £

Column A	Cost (£)
NNRTI	
EFV	245
NVP	188
PI/r	
LPV/r	361
ATZ/r ¹	411
FOS/r ²	402
SQV/r ²	393
IDV/r ^{2†}	256
TPV/r ^{4*}	734
PI	
ATZ 300 mg	371
NFV	321
NRTI	
ABC	261 [‡]
Entry inhibitor	
T20*	1349

r¹, r² or r⁴ indicates the number of ritonavir capsules per day.

*For experienced patients only.

†Not a preferred regimen but recognized potential cost savings.

‡Trizivir[®] £635.

ABC, abacavir; ATZ, atazanavir; IDV, indinavir; EFV, efavirenz; FOS, fosamprenavir; LPV, lopinavir; NFV, nelfinavir; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; r, ritonavir; SQV, saquinavir; TPV, tipranavir; T20, enfuvirtide.

Column B		Column C		Total cost
NRTI-1	Cost (£)	NRTI-2	Cost (£)	
ZDV 250 mg	196	3TC [‡] /FTC	179/192	375/388
TDF	300			479/492
ABC	261			440/453
ddl 400 mg	192			371/384
d4T 40 mg*	201			380/393
Combivir [®]				374
Truvada [®]				492
Kivexa [®]				439

*d4T/3TC is as effective as other regimens but more toxic and not a preferred regimen.

‡150 mg tablets.

ABC, abacavir; ddl, didanosine; d4T, stavudine; FTC, emtricitabine; NRTI, nucleoside reverse transcriptase inhibitor; 3TC, lamivudine; TDF, tenofovir; ZDV, zidovudine.

Reference

- 1 B Gazzard on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. *HIV Med* 2006; 7: 487–503.